Evaluation of aprotinin and tranexamic acid in different in vitro and in vivo models of fibrinolysis, coagulation and thrombus formation

Journal of Thrombosis and Haemostasis

Volumn 5, Issue 10, 2007, Pages 2113-2118

  Sperzel, Michael ^a   Huetter, J ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

Antifibrinolytic activity; Antithrombotic activity; Aprotinin; Bleeding; Thrombus formation; Tranexamic acid

Indexed keywords

APROTININ; TRANEXAMIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTERIOVENOUS SHUNT; ARTICLE; BLEEDING; BLEEDING TIME; BLOOD CLOTTING TEST; BLOOD CLOTTING TIME; CONCENTRATION RESPONSE; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MECHANISM; FIBRINOLYSIS; HEMOSTASIS; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SPECTROPHOTOMETRY; THROMBOGENESIS; THROMBUS;

ANIMALS; ANTIFIBRINOLYTIC AGENTS; APROTININ; ARTERIOVENOUS SHUNT, SURGICAL; BLOOD COAGULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRINOLYSIS; HEMOSTATICS; HUMANS; MALE; RATS; RATS, WISTAR; THROMBOSIS; TRANEXAMIC ACID;

EID: 34548827704     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02717.x     Document Type: Article

References (30)

1. Carless PA, Moxey AJ, Stokes BJ, Henry DA. Are antifibrinolytic drugs equivalent in reducing blood loss and transfusion in cardiac surgery? A meta-analysis of randomized head-to-head trials BMC Cardiovasc Disord 2005; 5: 19.
2. Sedrakyan A, Treasure T, Elefteriades JA. Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: A systematic review and meta-analysis of randomized clinical trials. J Thorac Cardiovasc Surg 2004; 128: 442-8.
3. Terrell MR, Walenga JM, Koza MJ, Pifarre R. Efficacy of aprotinin with various anticoagulant agents in cardiopulmonary bypass. Ann Thorac Surg 1996; 62: 506-11.
4. Hekmat K, Zimmermann T, Kampe S, Kasper SM, Weber HJ, Geissler HJ, Mehlhorn U. Impact of tranexamic acid vs. aprotinin on blood loss and transfusion requirements after cardiopulmonary bypass: A prospective, randomised, double-blind trial. Curr Med Res Opin 2004; 20: 121-6.
5. Murkin JM, Lux J, Shannon NA, Guiraudon GM, Menkis AH, McKenzie FN, Novick RJ. Aprotinin significantly decreases bleeding and transfusion requirements in patients receiving aspirin and undergoing cardiac operations. J Thorac Cardiovasc Surg 1994; 107: 554-61.
6. Levi M. Critical bleeding in surgery: Conventional therapy and new prospects. Minerva Anestesiol 2004; 70: 267-71.
7. Apeler H, Peters J, Schroder W, Schneider KH, Lemm G, Hinz V, Rossouw GJ, Dembowsky K. Expression, purification, biochemical and pharmacological characterization of a recombinant aprotinin variant. Arzneimittelforschung 2004; 54: 483-97.
8. Kang HM, Kalnoski MH, Frederick M, Chandler WL. The kinetics of plasmin inhibition by aprotinin in vivo. Thromb Res 2005; 115: 327-40.
9. Stassen JM, Lambeir AM, Matthyssens G, Ripka WC, Nystrom A, Sixma JJ, Vermylen J. Characterisation of a novel series of aprotinin-derived anticoagulants. I. In vitro and pharmacological properties. Thromb Haemost 1995; 74: 646-54.
10. Kuitunen A, Hiippala S, Vahtera E, Rasi V, Salmenpera M. The effects of aprotinin and tranexamic acid on thrombin generation and fibrinolytic response after cardiac surgery. Acta Anaesthesiol Scand 2005; 49: 1272-9.
11. Dietrich W. Reducing thrombin formation during cardiopulmonary bypass: is there a benefit of the additional anticoagulant action of aprotinin? J Cardiovasc Pharmacol 1996; 27: S50-7.
12. Hunt BJ, Segal H, Yacoub M. Aprotinin and heparin monitoring during cardiopulmonary bypass. Circulation 1992; 86: II410-2.
13. Dunn CJ, Goa KL. Tranexamic acid: A review of its use in surgery and other indications. Drugs 1999; 57: 1005-32.
14. Feindt P, Seyfert UT, Volkmer I, Straub U, Gams E. Celite and kaolin produce differing activated clotting times during cardiopulmonary bypass under aprotinin therapy. Thorac Cardiovasc Surg 1994; 42: 218-21.
15. Farooqi N, De Hert S, Vlaeminck R, De Bakker A, Govaerts E, Vermeyen K. Effects of low doses of aprotinin on clotting times activated with celite and kaolin. Acta Anaesthesiol Belg 1993; 44: 87-92.
16. Henry DA, Moxey AJ, Carless PA, O'Connell D, McClelland B, Henderson KM, Sly K, Laupacis A, Fergusson D. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2001; CD001886
17. Dowd NP., Karski JM, Cheng DC, Carroll JA, Lin Y, James RL, Butterworth J. Pharmacokinetics of tranexamic acid during cardiopulmonary bypass. Anesthesiology 2002; 97: 390-9.
18. Beath SM, Nuttall GA, Fass DN, Oliver WC Jr, Ereth MH, Oyen LJ. Plasma aprotinin concentrations during cardiac surgery: Full-versus half-dose regimens. Anesth Analg 2000; 91: 257-64.
19. Royston D. Blood-sparing drugs: Aprotinin, tranexamic acid, and epsilon-aminocaproic acid. Int Anesthesiol Clin 1995; 33: 155-79.
20. Engles L. Review and application of serine protease inhibition in coronary artery bypass graft surgery. Am J Health Syst Pharm 2005; 62: S9-14.
21. Laupacis A, Fergusson D. Drugs to minimize perioperative blood loss in cardiac surgery: Meta-analyses using perioperative blood transfusion as the outcome. The International Study of Peri-operative Transfusion (ISPOT) Investigators. Anesth Analg 1997; 85: 1258-67.
22. Khan TA, Bianchi C, Voisine P, Sandmeyer J, Feng J, Sellke FW. Aprotinin inhibits protease-dependent platelet aggregation and thrombosis. Ann Thorac Surg 2005; 79: 1545-50.
23. Samama CM, Mazoyer E, Bruneval P, Ciostek P, Bonnin P, Bonneau M, Roussi J, Bailliart O, Pignaud G, Viars P. Aprotinin could promote arterial thrombosis in pigs: A prospective randomized, blind study. Thromb Haemost 1994; 71: 663-9
24. Dietrich W., Dilthey G, Spannagl M, Jochum M, Braun SL, Richter JA. Influence of high-dose aprotinin on anticoagulation, heparin requirement, and celite- and kaolin-activated clotting time in heparin-pretreated patients undergoing open-heart surgery. A double-blind, placebo-controlled study. Anesthesiology 1995; 83: 679-89.
25. Khan MM, Gikakis N, Miyamoto S, Rao AK, Cooper SL, Edmunds LH Jr, Colman RW. Aprotinin inhibits thrombin formation and monocyte tissue factor in simulated cardiopulmonary bypass. Ann Thorac Surg 1999; 68: 473-8.
26. Dietrich W, Spannagl M, Jochum M, Wendt P, Schramm W, Barankay A, Sebening F, Richter JA. Influence of high-dose aprotinin treatment on blood loss and coagulation patterns in patients undergoing myocardial revascularization. Anesthesiology 1990; 73: 1119-26.
27. Poston RS, White C, Gu J, Brown J, Gammie J, Pierson RN, Lee A, Connerney I, Avari T, Christenson R, Tandry U, Griffith BP. Aprotinin shows both hemostatic and antithrombotic effects during off-pump coronary artery bypass grafting. Ann Thorac Surg 2006; 81: 104-10.
28. Risch A, Dorscheid E, Stein G, Seyfert UT, Grundmann U. The effect of aprotinin and tranexamic acid on fibrinolysis and thrombin generation during cardiopulmonary bypass. Anaesthesist 2000; 49: 279-85.
29. Patterson RH Jr, Harpel P. The effect of epsilon aminocaproic acid and tranexamic acid on thrombus size and strength in a simulated arterial aneurysm. J Neurosurg 1971; 34: 365-71.
30. Lockyer S, Kambayashi J. Demonstration of flow and platelet dependency in a ferric chloride-induced model of thrombosis. J Cardiovasc Pharmacol 1999; 33: 718-25.